Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

The best metric is not weight, but a particularly toxic kind of fat.

Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

A new study shows Zepbound beats Wegovy for weight loss. "It's NOT normal to snore; get it checked out. Sleep apnea worsens ...

In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...

New data suggests the weight-loss drug Wegovy may significantly reduce the risk of heart disease even before users experience ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...